Development of New Generation Adenovirus Type 5 Foot-and-Mouth Disease Vaccines with Improved Performance
Foreign Animal Disease Research
Project Number: 8064-32000-057-57
Specific Cooperative Agreement
Start Date: Feb 01, 2014
End Date: Sep 30, 2016
Utilizing the first generation adenovirus vectored Foot-and-Mouth Disease Virus Vaccine (Ad5-FMD) in combination with adenovirus vectored porcine interferon alpha (Ad5-poIFNalpha), it has been demonstrated that swine can be protected as early as one day and for approximately five days post vaccination and there is an enhancement of the long-term level of immunity. Utilization of pattern recognition receptor (PRR) agonists, such as polyIC, alone or in combination with interferons (IFNs),can also protect swine against FMDV. Preliminary studies have shown that utilization of Ad5-FMD vaccine in combination with polyICLC has also improved vaccine potency. This collaborative research project seeks to construct a modified Ad5 vector to fully protect swine against FMD, increasing the stability of transgene expression with the ability to express multiple transgenes or inducers of innate immunity from the same vector.
ARS, PIADC will provide Stony Brook University (SB) with Ad5-FMD vaccine DNA constructs. Utilizing recombination DNA technology, SB will manipulate the material and implement experimental approaches to reduce contamination of Adenovirus vaccine vectors with replication-competent adenovirus (RCA). SB will also construct adenovirus vectors that will allow expression of multiple genes or RNAs from the same vector. A master seed of the derived viruses will be generated and sent to ARS, PIADC. Scientists from ARS, PIADC will propagate the new viruses and test them in vitro and if successfully, in vivo.